BioPharmSignal logoBioPharmSignal

Biotech News

Celldex to Present at Upcoming Investor Conference

Celldex Therapeutics (CLDX)Celldex TherapeuticsConference / presentation

Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference on Tuesday, April 14 at 3:30 pm ET.

The webcast of the presentations will be available on the " Events & Presentations " page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event.

About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit www.celldex.com .

Company Contact Sarah Cavanaugh Senior Vice President, Corporate Affairs & Administration (508) 864-8337 [email protected]

Patrick Till Meru Advisors (484) 788-8560 [email protected]

Related news

CLDXCelldex Therapeutics2026-06-10 20:01 EST

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

KNSAKiniksa2026-05-29 20:01 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

NRIXNurix Therapeutics2026-04-07 11:00 EST

Nurix Therapeutics to Participate in Upcoming Investor Conference

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ARGXArgenx2026-05-06 20:30 EST

argenx to Present at BofA Securities 2026 Health Care Conference

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

REGNRegeneron Pharmaceuticals2026-04-20 20:05 EST

Regeneron Announces Investor Conference Presentations

CLDXCelldex Therapeutics2026-07-15 20:01 EST

Celldex Announces Planned Transition of Chief Financial Officer

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

ANABAnaptysBio, Inc.2026-05-04 20:15 EST

Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference

View all latest news

Celldex Therapeutics

Celldex Therapeutics is an immunology company focused on mast-cell and inflammatory disease biology. Its pipeline is concentrated in high-unmet-need immune disorders.

Recent company news

CLDXCelldex Therapeutics2026-07-21 20:01 EST

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

CLDXCelldex Therapeutics2026-07-15 20:01 EST

Celldex Announces Planned Transition of Chief Financial Officer

CLDXCelldex Therapeutics2026-06-14 14:21 EST

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

CLDXCelldex Therapeutics2026-06-14 09:15 EST

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

CLDXCelldex Therapeutics2026-06-10 20:01 EST

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

Stock data

Close
35.65 USD
Market cap
2.27B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States